Bonuomo V, Ferrarini I, Dell'Eva M, Sbisà E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World J Virol 2021; 10(6): 312-325 [PMID: 34909405 DOI: 10.5501/wjv.v10.i6.312]
Corresponding Author of This Article
Carlo Visco, MD, Professor, Section of Haematology, Department of Medicine, University of Verona, P. Le L.A. Scuro 10, Verona 37134, Italy. carlo.visco@univr.it
Research Domain of This Article
Hematology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Valentina Bonuomo, Isacco Ferrarini, Michele Dell'Eva, Eugenio Sbisà, Mauro Krampera, Carlo Visco, Section of Haematology, Department of Medicine, University of Verona, Verona 37134, Italy
Author contributions: Bonuomo V, Ferrarini I and Visco C designed and conceptualized the review procedure; Bonuomo V and Ferrarini I wrote the first concept of the article; Bonuomo V performed the literature research; Bonuomo V, Ferrarini I and Visco C analyzed the data and wrote the final manuscript; All authors reviewed and amended subsequent versions and discussed the clinical aspects and implications of the study.
Conflict-of-interest statement: The authors do not have any conflict of interest. No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Carlo Visco, MD, Professor, Section of Haematology, Department of Medicine, University of Verona, P. Le L.A. Scuro 10, Verona 37134, Italy. carlo.visco@univr.it
Received: April 21, 2021 Peer-review started: April 21, 2021 First decision: July 7, 2021 Revised: July 16, 2021 Accepted: August 9, 2021 Article in press: August 9, 2021 Published online: November 25, 2021 Processing time: 214 Days and 23.3 Hours
Core Tip
Core Tip: Recently, the scientific literature has been widely occupied by reports on severe acute respiratory syndrome coronavirus 2 infection. However, patients with cancer have been under-represented, and patients with lymphoma have rarely been described. The real impact of this tremendous pandemic on the life expectancy of patients with different subtypes of lymphoma is still unknown, especially in relation to chemo-, chemo-immunotherapy and/or biologic treatments. Furthermore, the relationship between lymphoma patients’ characteristics and the infection behavior is undescribed. With this review we pointed out what literature clarifies in the prognosis and management of patients with lymphoma during the coronavirus disease 2019 pandemic.
